Heavy Volume And Pre-Market Movement For NPS Pharmaceuticals (NPSP)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified NPS Pharmaceuticals ( NPSP) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified NPS Pharmaceuticals as such a stock due to the following factors:

  • NPSP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $79.0 million.
  • NPSP traded 411,054 shares today in the pre-market hours as of 8:43 AM, representing 15.6% of its average daily volume.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in NPSP with the Ticky from Trade-Ideas. See the FREE profile for NPSP NOW at Trade-Ideas

More details on NPSP:

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPSP has a PE ratio of 687.5. Currently there are 9 analysts that rate NPS Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for NPS Pharmaceuticals has been 1.5 million shares per day over the past 30 days. NPS has a market cap of $2.9 billion and is part of the health care sector and drugs industry. The stock has a beta of -0.38 and a short float of 12.5% with 2.76 days to cover. Shares are down 5.9% year-to-date as of the close of trading on Monday.

If you liked this article you might like

Mylan Bids $29 Billion for Perrigo in Latest Big Pharma Deal

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

Valeant Boosts Offer for Salix to $15.8 Billion, Endo Drops Bid

'Mad Money' Lightning Round: Ambarella Is Like Putting a Gun to Your Head

Jim Cramer's 'Mad Money' Recap: Zombie Stocks That Will Rise From the Dead